MOA Life Plus Co. Ltd. (KOSDAQ:142760)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,751.00
+21.00 (1.21%)
Last updated: Oct 2, 2025, 9:00 AM KST
1.21%
Market Cap70.22B
Revenue (ttm)12.16B
Net Income (ttm)-12.87B
Shares Out39.05M
EPS (ttm)-360.31
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume213,852
Average Volume209,757
Open1,730.00
Previous Close1,730.00
Day's Range1,695.00 - 1,772.00
52-Week Range999.00 - 2,250.00
Beta1.36
RSI71.52
Earnings DateNov 11, 2025

About MOA Life Plus

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company’s pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw ma... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 42
Stock Exchange KOSDAQ
Ticker Symbol 142760
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.